Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT. Issue 12 (14th October 2020)

• Record Type: Journal Article
• Authors: Martínez, Carmen; Boumendil, Ariane; Romejko-Jarosinska, Joanna; Anagnostopoulos, Achilles; Faber, Edgar; Poiré, Xavier; Yakoub-Agha, Ibrahim; Akhtar, Saad; Gurman, Gunhan; Pavone, Vincenzo; Halaburda, Kazimierz; Sousa, Aida Botelho; Ghesquières, Hervé; Finel, Hervé; Khvedelidze, Irma; Montoto, Silvia; Sureda, Anna
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 12(2020)
• Page Start: 2915
• Page End: 2922
• Publication Date: 2020-10-14
• Subjects: Hodgkin lymphoma -- relapse -- refractory -- autologous hematopoietic stem cell transplantation; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1789624
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The purpose of this study was to analyze the results of second autologous hematopoietic stem cell transplantation (ASCT2) for patients with relapsed/refractory Hodgkin lymphoma (HL) after a first transplantation (ASCT1). Outcomes for 56 patients receiving an ASCT2 registered in the EBMT database were analyzed. The 4-year cumulative incidences of non-relapse mortality and disease relapse/progression were 5% and 67%, respectively. The 4-year overall survival (OS) and progression-free survival (PFS) were 62% and 28%. In univariate analysis, relapse of HL within 12 months of ASCT1 was associated with a worse OS (35% versus 76%, p = 0.01) and PFS (19% versus 29%, p = 0.059). Chemosensitivity at ASCT2 predicted better outcomes (4-year OS 72% versus 29%, p = 0.002; PFS 31% versus 12%, p = 0.015). This series shows that ASCT2 is a safe procedure and a relatively effective option for patients with late relapses after ASCT1 and with chemosensitive disease who are not eligible for an allogeneic transplant.